192 related articles for article (PubMed ID: 10506306)
1. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
Nurnberg HG; Hensley PL; Thompson PM; Paine SS
Psychiatr Serv; 1999 Oct; 50(10):1351-3. PubMed ID: 10506306
[TBL] [Abstract][Full Text] [Related]
2. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
3. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
4. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
5. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN
Value Health; 2000; 3(3):208-21. PubMed ID: 16464185
[TBL] [Abstract][Full Text] [Related]
6. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
7. Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Dobscha SK; Anderson TA; Hoffman WF; Winterbottom LM; Turner EH; Snodgrass LS; Hauser P
Psychiatr Serv; 2003 Feb; 54(2):195-200. PubMed ID: 12556600
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Serrano-Blanco A; Pinto-Meza A; Suárez D; Peñarrubia MT; Haro JM;
Acta Psychiatr Scand Suppl; 2006; (432):39-47. PubMed ID: 17087814
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.
Rendas-Baum R; Yang M; Gricar J; Wallenstein GV
Appl Health Econ Health Policy; 2010; 8(2):129-40. PubMed ID: 20175591
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of major selective serotonin-reuptake inhibitors in a managed care population.
Panzarino PJ; Xuan J
Manag Care Interface; 2001 Apr; 14(4):59-65. PubMed ID: 11339023
[TBL] [Abstract][Full Text] [Related]
11. A cost-effective approach to the use of selective serotonin reuptake inhibitors in a Veterans Affairs Medical Center.
Singletary T; North DS; Weiss M; Marman G
Am J Manag Care; 1997 Jan; 3(1):125-9. PubMed ID: 10169244
[TBL] [Abstract][Full Text] [Related]
12. Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities.
Voris JC
J Clin Psychol; 1999 Jan; 55(1):129-33. PubMed ID: 10100839
[TBL] [Abstract][Full Text] [Related]
13. Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
Dewa CS; Hoch JS; Goering P
Clin Ther; 2001 Feb; 23(2):292-306. PubMed ID: 11293562
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Nurnberg HG; Thompson PM; Hensley PL
J Clin Psychiatry; 1999 Sep; 60(9):574-9. PubMed ID: 10520974
[TBL] [Abstract][Full Text] [Related]
15. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
16. The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization.
Roy-Byrne PP; Clary CM; Miceli RJ; Colucci SV; Xu Y; Grudzinski AN
J Clin Psychiatry; 2001 Sep; 62(9):678-82. PubMed ID: 11681762
[TBL] [Abstract][Full Text] [Related]
17. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
18. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
19. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW
Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
